輝瑞(PFE)旗下抗感染創新藥康新博®全劑型兒科適應症獲中國藥監局批准

金吾財訊

05/27

金吾財訊 | 5月27日，輝瑞(PFE)中國宣佈，旗下抗感染重磅創新藥物康新博®(Cresemba®)200mg注射劑型(通用名：注射用硫酸艾沙康唑)和100mg口服膠囊劑型(通用名：硫酸艾沙康唑膠囊)新增兒科適應症獲得中國國家藥品監督管理局(NMPA)批准，進一步完善了從兒童到成人的全年齡段治療覆蓋。輝瑞全球高級副總裁、輝瑞中國區總裁Jean-Christophe Pointeau表示：「兒童侵襲性真菌病診療難度大、死亡風險高，患兒家庭常面臨巨大的身心壓力與經濟負擔。基於積極的臨床循證數據，康新博®成功將適用人群拓展至低齡兒童，這在提升治療可及性與便利性的同時，更有望直接改善患者的整體生存獲益。」

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/news/2638570216"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638570216\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638570216?lang=zh_TW&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","is_english":false,"pubTime":"2026-05-27 16:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638570216","market":"hk","top_or_hot":-1,"title":"輝瑞(PFE)旗下抗感染創新藥康新博®全劑型兒科適應症獲中國藥監局批准","media":"金吾財訊","content":"<html><body><p>金吾財訊 | 5月27日，<a href=\"https://laohu8.com/S/PFE\">輝瑞</a>(PFE)中國宣佈，旗下抗感染重磅創新藥物康新博®(Cresemba®)200mg注射劑型(通用名：注射用硫酸艾沙康唑)和100mg口服膠囊劑型(通用名：硫酸艾沙康唑膠囊)新增兒科適應症獲得中國國家藥品監督管理局(NMPA)批准，進一步完善了從兒童到成人的全年齡段治療覆蓋。輝瑞全球高級副總裁、輝瑞中國區總裁Jean-Christophe Pointeau表示：「兒童侵襲性真菌病診療難度大、死亡風險高，患兒家庭常面臨巨大的身心壓力與經濟負擔。基於積極的臨床循證數據，康新博®成功將適用人群拓展至低齡兒童，這在提升治療可及性與便利性的同時，更有望直接改善患者的整體生存獲益。」</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>輝瑞(PFE)旗下抗感染創新藥康新博®全劑型兒科適應症獲中國藥監局批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n輝瑞(PFE)旗下抗感染創新藥康新博®全劑型兒科適應症獲中國藥監局批准\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">金吾財訊 </p>\n<p class=\"h-time smaller\">2026-05-27 16:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>金吾財訊 | 5月27日，<a href=\"https://laohu8.com/S/PFE\">輝瑞</a>(PFE)中國宣佈，旗下抗感染重磅創新藥物康新博®(Cresemba®)200mg注射劑型(通用名：注射用硫酸艾沙康唑)和100mg口服膠囊劑型(通用名：硫酸艾沙康唑膠囊)新增兒科適應症獲得中國國家藥品監督管理局(NMPA)批准，進一步完善了從兒童到成人的全年齡段治療覆蓋。輝瑞全球高級副總裁、輝瑞中國區總裁Jean-Christophe Pointeau表示：「兒童侵襲性真菌病診療難度大、死亡風險高，患兒家庭常面臨巨大的身心壓力與經濟負擔。基於積極的臨床循證數據，康新博®成功將適用人群拓展至低齡兒童，這在提升治療可及性與便利性的同時，更有望直接改善患者的整體生存獲益。」</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"300833","article_id":"2638570216","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638570216","pubTimestamp":1779869935,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾財訊","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾財訊 | 5月27日，輝瑞 中國宣佈，旗下抗感染重磅創新藥物康新博200mg注射劑型和100mg口服膠囊劑型新增兒科適應症獲得中國國家藥品監督管理局批准，進一步完善了從兒童到成人的全年齡段治療覆蓋。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4588":"碎股","LU0122379950.USD":"贝莱德世界健康科学A2","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4007":"制药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4581":"高盛持仓","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4599":"减肥药","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4585":"ETF&股票定投概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4534":"瑞士信贷持仓","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0234572021.USD":"高盛美国核心股票组合Acc","PFE":"辉瑞","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999002232.USD":"Allianz Global High Payout USD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0058720904.USD":"联博国际健康护理基金A","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4592":"伊斯兰概念","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD"},"translate_title":"Kangxinbo, an innovative anti-infective drug owned by Pfizer (PFE) ® Full-dosage pediatric indication approved by China Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.97},"content_text":"金吾財訊 | 5月27日，輝瑞(PFE)中國宣佈，旗下抗感染重磅創新藥物康新博®(Cresemba®)200mg注射劑型(通用名：注射用硫酸艾沙康唑)和100mg口服膠囊劑型(通用名：硫酸艾沙康唑膠囊)新增兒科適應症獲得中國國家藥品監督管理局(NMPA)批准，進一步完善了從兒童到成人的全年齡段治療覆蓋。輝瑞全球高級副總裁、輝瑞中國區總裁Jean-Christophe Pointeau表示：「兒童侵襲性真菌病診療難度大、死亡風險高，患兒家庭常面臨巨大的身心壓力與經濟負擔。基於積極的臨床循證數據，康新博®成功將適用人群拓展至低齡兒童，這在提升治療可及性與便利性的同時，更有望直接改善患者的整體生存獲益。」","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}